Yoodo Breaks New Ground in the Malaysian Mobile Market
MATRIXX Software today announced that Yoodo, Malaysia’s newest mobile player, has launched as the first mobile service in the country that enables customers to completely customize their mobile plan. Challenging the status quo, Yoodo is a new mobile brand that gives their customers the ultimate choice and control over their plans while delivering simple, clear and engaging customer service.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180131005338/en/
Yoodo has thrown out the rules of the mobile market and is offering customizable packages across voice, data, messaging and content with up to 1,000 combinations possible. Customers can change, upgrade or downgrade their package at any time via their mobile app. Customers don’t have to choose prepaid or contract, but rather get the best of both worlds with the ability to dynamically add-on or auto-renew as they please. Other highlights of the service include: self-registration, immediate SIM delivery, roam like home, add-on boosters, rewards, and non-intrusive, curated promotions triggered by location or spending behavior.
“Traditional mobile operators design plans based on what they want to sell the customer, developing various plans and features that don’t fit most customer’s individual needs. We’ve flipped that on its head and enabled customers to make their mobile plans work for them, by providing a real-time, on-demand service that lets people experience full control,” said Farid Yunus, Head of Yoodo.
Yoodo’s goal is to provide consumers with simpler and clearer options for cutting edge digital products and services, leading to a better overall experience. Simpler means there are fewer steps for sign up, changing plans, account inquiries, paying, disconnection and reconnection. Clearer means no hidden charges or contracts, with real-time account and spending information available at all times through the mobile app.
Powered by MATRIXX Software, Yoodo built and deployed a digital Telco infrastructure that could enable their market-entry strategy as well as their longer-term ambitions. Yoodo chose MATRIXX Software’s digital commerce platform because of its unique ability to deliver first-class digital experience to their customers, while also providing agility and innovation to their operations.
Farid from Yoodo explained further, “Our goal is to break the boundaries of the traditional mobile business, and to do so we needed systems and expertise to build a disruptive digital operating model. We chose MATRIXX Software as they are the leading supplier providing new and innovative solutions and technologies so that Telco's can leapfrog into the era of digital and mobile commerce.”
About YooDo
Launched in January 2018, Yoodo is an independent digital mobile service that is owned and operated by Celcom Axiata Bhd. It offers the country’s first truly customisable mobile service, with complete transparency, flexibility and customer convenience. For more information on Yoodo, log on to yoodo.com.my or look up yoodoMY on Facebook, Instagram, YouTube and Twitter.
About MATRIXX Software
Silicon Valley based MATRIXX Software is committed to helping Telco’s reinvent themselves into leaders of the digital economy. Our multi-patented MATRIXX Digital Commerce platform was built from scratch to serve as the foundation for next-generation IT architectures capable of powering rapid transformation. Through innovations in engineering, product, sales and deployment, we empower Communications Service Providers with the speed, agility and autonomy they need to give their customers modern, digital experiences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180131005338/en/
Contact information
Mercury Global Partners for MATRIXX
Natalee Gibson, +1 720-648-5784
Managing
Director
matrixx@mercuryglobalpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom